AntriaBio

Financials

Investors

Financials

v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2019
Jun. 30, 2018
Current assets:    
Cash $ 15,344,013 $ 1,645,872
Other current assets 13,992 361,915
Total current assets 15,358,005 2,007,787
Non-current assets:    
Property and equipment, net 40,105 368,374
Intangible assets, net 31,561 37,030
Lease deposits and other 34,700 89,691
Total assets 15,464,371 2,502,882
Current liabilities:    
Accounts payable and accrued expenses 954,277 1,706,154
Accrued payroll 1,156,717 770,976
Current portion of license fees payable to Xoma 4,500,000 0
Convertible notes payable, net 10,000 3,434,611
Interest payable 2,762 148,372
Embedded derivative liability 0 73,904
Deferred lease liability 0 113,997
Total current liabilities 6,623,756 6,248,014
Non-current liabilities:    
License fees payable to Xoma, net of current portion 4,000,000 0
Long-term portion of accrued payroll 162,500  
Long-term portion of deferred lease liability and sublease deposits 28,499 215,623
Total liabilities 10,814,755 6,463,637
Commitments and contingencies (Note 10)
Stockholders' equity (deficit):    
Preferred Stock, including $0.001 par value; 20,000,000 shares authorized: 5,000,000 shares designated as Series AA; 3,267,515 shares issued and outstanding as of March 31, 2019 (none in 2018) 31,140,117 0
Common Stock, $0.001 par value, 500,000,000 shares authorized; 61,866,319 and 62,166,309 shares issued and outstanding as of March 31, 2019 and June 30, 2018, respectively 61,866 62,168
Additional paid-in capital 97,203,841 90,160,815
Accumulated deficit (123,756,208) (94,183,738)
Total stockholders' equity (deficit) 4,649,616 (3,960,755)
Total liabilities and stockholders' equity (deficit) $ 15,464,371 $ 2,502,882
v3.19.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Research and development:        
Compensation and benefits $ 869,354 $ 1,569,840 $ 1,798,173 $ 4,553,650
Consultants and outside costs 134,609 157,759 307,771 521,918
Material manufacturing costs 8,912 219,192 554,433 872,883
Facilities and other costs 132,884 484,316 670,653 1,466,123
Total research and development 15,121,759 2,496,197 17,360,761 10,219,923
General and administrative:        
Compensation and benefits 1,101,938 1,797,385 3,733,486 5,265,306
Professional fees 199,117 181,258 406,658 618,251
Investor relations 194,276 64,347 252,236 257,923
Other general and administrative 419,562 414,297 1,006,489 1,060,168
Total general and administrative 1,914,893 2,457,287 5,398,869 7,201,648
Operating loss (17,036,652) (4,953,484) (22,759,630) (17,421,571)
Interest expense:        
Beneficial conversion feature (2,233,000) 0 (2,233,000) 0
Accretion of debt discount (472,071) 0 (2,053,234) 0
At contractual rate (42,840) (53,363) (660,190) (53,510)
Derivative gains 0 7,487 73,904 7,985
Rent income 0 31,406 153,071 95,082
Interest income 11,758 116 11,821 977
Gain on lease termination 0 0 167,788 0
Total non-operating income (expense) (2,736,153) (14,354) (4,539,840) 50,534
Net loss (19,772,805) (4,967,838) (27,299,470) (17,371,037)
Net loss attributable to common stockholders $ (22,045,805) $ (4,967,838) $ (29,572,470) $ (17,371,037)
Net loss per common share - basic and diluted $ (0.36) $ (0.09) $ (0.48) $ (0.32)
Weighted average number of common shares outstanding - basic and diluted 61,866,319 54,073,309 62,053,126 53,573,410
Clinical trial costs        
Research and development:        
Cost of Goods and Services Sold $ 0 $ 65,090 $ 3,731 $ 1,626,844
License costs        
Research and development:        
Cost of Goods and Services Sold $ 13,976,000 $ 0 $ 14,026,000 $ 1,178,505
v3.19.1
Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (27,299,470) $ (17,371,037)
Stock-based compensation expense 2,389,413 4,175,493
Beneficial conversion feature attributable to Fiscal 2018 Notes 2,233,000 0
Accretion of debt discount and issuance costs 2,053,234 31,697
Depreciation and amortization expense 44,811 805,643
Loss on sale of fixed assets 12,268 0
Impairment of long-lived assets 33,039 0
Fair value of warrants issued for services 9,466 543,507
Gain on lease termination (167,788) 0
Derivative gains (73,904) (7,985)
Changes in operating assets and liabilities:    
Decrease in other assets 292,054 91,831
Increase (decrease) in accounts payable and accrued liabilities (220,163) 1,480,496
Increase in license fees payable to Xoma 8,500,000 0
Increase in interest payable 654,562 20,252
Net Cash Used In Operating Activities (11,539,478) (10,230,103)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Proceeds from sale of equipment 278,234 0
Refund of deposit 0 187,500
Purchase of fixed assets (40,615) (5,816)
Net Cash Provided By Investing Activities 237,619 181,684
Proceeds from Series AA Financing:    
Exclusivity Payment 1,500,000 0
Closing payment for issuance of Series AA Preferred Stock 23,500,000 0
Proceeds from issuance of Common Stock 0 4,500,000
Payment of offering costs 0 (60,000)
Proceeds from convertible notes payable 0 1,200,000
Net Cash Provided by Financing Activities 25,000,000 5,640,000
Net increase (decrease) in cash 13,698,141 (4,408,419)
Cash at beginning of period 1,645,872 4,486,538
Cash at end of period 15,344,013 78,119
Cash paid for    
Interest 0 0
Income taxes 0 0
Issuance of Series AA Preferred Stock for conversion of:    
Principal balance of Fiscal 2018 Notes 5,340,000 0
Exclusivity Payment 1,500,000 0
Accrued interest under Fiscal 2018 Notes 800,117 0
Fair value of warrant modification issued for debt discount 137,845 217,000
Fair value of embedded derivative for debt discount 0 100,000
Surrender of 299,990 shares of Common Stock for no consideration $ 0 $ 0